Skip to main content

Search

Reset all filters
737 Result(s)
Sort by

Giotrif®

Giotrif®

For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have activating epidermal growth factor receptor (EGFR) mutations. For the treatment of patients with locally advanced or metastatic NSCLC of squamous hist
Uncommon_Mutations_Database

Uncommon_Mutations_Database

New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use
New vaccine against Bovine Respiratory Disease

New vaccine against Bovine Respiratory Disease

Boehringer Ingelheim’s Bovalto Respi Intranasal is a new respiratory vaccine for active immunization of cattle against Bovine Respiratory Disease.
Embracing diversity in clinical trials

Embracing diversity in clinical trials

At Boehringer Ingelheim, we understand the crucial need of embracing diversity in clinical trials as an opportunity to enable more equitable healthcare.
Vienna

Vienna

Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
Overcoming heartworm disease for homeless pets

Overcoming heartworm disease for homeless pets

Heartworm-free pets soar to new lives. Together with our Greater Good Charity partners, our colleagues helped bring shelter dogs to forever homes.
Contact Us

Contact Us

Contact our partnering team to discuss your project and learn more about how we can work together.
What we do

What we do

Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.